ABT · Abbott Laboratories
$102.872026-05-17Sector: Healthcare; Industry: Medical - Devices; Sub-Industry: Health Care Equipment
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$75
-26.7% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($65 · $83) Analysts Range ($120 · $158) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $43.1B | — | 23.3% | 13.9% | $8.6B | −$114MM | $8.5B | 5.9% | — | 16.7% | $51.8B | $4.05 | — |
| 2022.Q4 | $43.7B | 1.3% | 20.9% | 16.5% | $7.6B | −$797MM | $6.8B | 7.3% | — | 14.7% | $51.8B | $3.97 | — |
| 2023.Q4 | $40.1B | -8.1% | 17.5% | 14.1% | $6.0B | −$4.0B | $2.0B | 7.1% | — | 11.4% | $54.1B | $3.28 | — |
| 2024.Q4 | $42.0B | 4.6% | 17.7% | 0.0% | $14.2B | −$8.9B | $5.3B | 8.0% | — | 24.5% | $62.2B | $7.67 | — |
| 2025.Q4 | $44.3B | 5.7% | 19.8% | 22.9% | $6.8B | −$692MM | $6.1B | 7.6% | — | 10.6% | $65.9B | $3.73 | 20.5 |
| italics below = DCF projection · 10yr Rev CAGR: 6.6% |
| 2026.Q4 | $48.3B | +9.0% | 19.6% | 22.6% | $7.3B | −$4.8B | $2.6B | 7.5% | $2.4B | 10.8% | $70.6B | $3.86 | 26.7 |
| 2027.Q4 | $52.1B | +7.8% | 20.2% | 22.4% | $8.2B | −$4.8B | $3.3B | 7.6% | $2.9B | 11.2% | $75.5B | $4.28 | 24.0 |
| 2028.Q4 | $56.0B | +7.4% | 20.8% | 22.1% | $9.1B | −$5.3B | $3.8B | 7.7% | $3.0B | 11.6% | $80.8B | $4.75 | 21.7 |
| 2029.Q4 | $60.3B | +7.8% | 21.3% | 21.8% | $10.0B | −$5.9B | $4.1B | 7.8% | $3.1B | 12.0% | $86.7B | $5.27 | 19.5 |
| 2030.Q4 | $64.7B | +7.2% | 21.3% | 21.5% | $10.8B | −$6.0B | $4.8B | 8.0% | $3.3B | 12.1% | $92.7B | $5.68 | 18.1 |
|
| Term. Yr+ | $87.4B | 4.1% | 19.4% | 20.0% | $13.5B | −$4.2B | $9.3B | 8.6% | $95.6B | 13.1% | — | — | — |
Active scenario IV: $75 (-26.7% vs market)